Responsiveness and predictive value of EDSS and MSFC in primary progressive MS

Neurology

Volumn 70, Issue 13 PART 2, 2008, Pages 1084-1091

  Kragt, J J ^a   Thompson, A J ^b   Montalban, X ^c   Tintore M ^c   Rio J ^c   Polman, C H ^a   Uitdehaag, B M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SENSIBILITY;

EID: 41549156010     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000288179.86056.e1     Document Type: Article

References (20)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
2. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;123(Pt 5):1027-1040.
3. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(Pt 5):871-882.
4. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687.
5. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996;46:1613-1619.
6. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51.
7. Thompson AJ. Promises, promises. Ann Neurol 2007;61:1-2.
8. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
9. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
11. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Administration and scoring manual for the Multiple Sclerosis Functional Composite. New York; 2001.
12. Ravnborg M, Blinkenberg M, Sellebjerg F, Ballegaard M, Larsen SH, Sorensen PS. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. Mult Scler 2005;11:81-84.
13. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27(3 Suppl):S178-S189.
14. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56:1324-1330.
15. Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-406.
16. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168-169.
17. Goodkin DE. EDSS reliability. Neurology 1991;41:332.
18. Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60.
19. Cohen J. Statistical Power Analysis for the Behavorial Sciences. New York: Academic Press, 1977.
20. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;126(Pt 11):2528-2536.